· Pharmaceutical service provider advances its expansion with a 50,000 sqm facility
· Strategic investments in the EU and US strengthen Vetter’s global footprint
· Groundbreaking ceremony featuring state and regional representatives, and project partners
Saarlouis / Ravensburg, May 13, 2026: Vetter, a leading Contract Development and Manufacturing Organization (CDMO), is celebrating the start of construction on its new site in Saarlouis with a traditional groundbreaking ceremony today. During the first construction phase, the company will build a state-of-the-art facility for the commercial production of injectable drugs on the 95-acre industrial site. In total, Vetter will invest almost half a billion euros in the site by the planned commissioning in 2031, underscoring its role as an industry leader for quality and technology. Once operational, the facility will create 400 to 500 new jobs, a figure that could rise to 1,500 by the final stage of the first construction phase. Ultimately, up to 2,000 jobs could be created.
In the first expansion phase, Vetter will build a 50,000 sqm manufacturing site, along with production-related facilities including laboratories and warehouses. Initially, three state-of-the-art cleanrooms are planned for the aseptic production of innovative and complex drug products: two for filling pre-sterilized syringes and one for filling vials.
Executives and officials at the groundbreaking ceremony
Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family: "Today's groundbreaking ceremony marks a decisive step for the future of our family business. With our new location in Saarlouis, we are setting the course for further sustainable growth. We are creating the conditions to further expand our capacities in the field of complex drug product manufacturing. This underlines our continuous approach to offer our international customers the resources, quality and reliability they need and are accustomed to from us."
Anke Rehlinger, Minister President of Saarland: “Today is a good day for Saarland. With Vetter, a strong and innovative company, new opportunities are opening up for the region and its people. Here in Saarlouis, it is clear, that structural change succeeds when we actively shape it.”
Jürgen Barke, Minister of Economic Affairs, Innovation, Digitalization and Energy of Saarland: “An advanced technology investment of this kind positions us as one of the most sought-after locations for the pharmaceutical industry and demonstrates how transformation succeeds: with new, sustainable jobs and a strong, future-oriented industry. This will set off ripple effects unlike anything we have experienced before.”
Global investments in the future
For over 75 years, Vetter has stood for quality, innovation and responsibility, helping patients worldwide to achieve a better quality of life. In order to meet the growing demand and increasing market requirements, the CDMO is sustainably investing in its pharmaceutical production sites in Germany, Austria and the US. With its new location in Saarlouis, Vetter is significantly expanding its capacities once again.
© Vetter Pharma International GmbH: Representatives of the
pharmaceutical service provider Vetter, the economic development agency gwSaar,
and political representatives from the city, district, and state at the
symbolic groundbreaking ceremony for the new production site in Saarlouis (from
left to right): Nicholas H. Vetter, Thomas Schuck,
Henryk Badack, Jürgen Barke, Gunther Strothe, Anke Rehlinger, Senator h.c. Udo
J. Vetter, Marc Speicher, Patrik Lauer, Wolfgang Kerkhoff.
About Vetter
Vetter is a leading Contract Development and Manufacturing
Organization (CDMO) with headquarters in Ravensburg, Germany, and production
facilities in Germany, Austria, and the US. As a global player, the independent
pharmaceutical service provider is also present in the Asia-Pacific markets of
Japan, China, South Korea and Singapore with sales locations. Around the world
renowned pharma and biotech companies benefit from decades of experience, high
quality, modern technologies, reliability, and commitment of its 7,300
employees. In close collaboration with its customers, the Vetter team helps
enable the supply to patients all over the world with medicines, many of which
are vital. The CDMO provides support from drug product development through
clinical and commercial filling to a wide range of assembly and packaging
services for vials, syringes, and cartridges. With innovative approaches,
Vetter develops prefilled drug-delivery systems together with its customers to
continuously improve patient safety, comfort, and compliance. Vetter takes
responsibility for sustainable practices and operates as a socially and
ethically responsible corporate citizen. The CDMO is a member of the UN
Global Compact and Science Based Target initiative (SBTi) and
received platinum status in the renowned EcoVadis ranking. Multiple awards such
as the CDMO Leadership Awards, Frost & Sullivan Customer Value
Leadership Award and the recognition of Best
Managed Company emphasize Vetter’s commitment to sustainable business.
Founded in Ravensburg in 1950, the company remains family-owned to this day.
For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.
Contact
Vetter Pharma International GmbH
Markus Kirchner
Company Spokesperson / Media Relations
Eywiesenstraße 5
88212 Ravensburg
Germany
Phone: +49 (0)751-3700-3729
E-Mail: PRnews@vetter-pharma.com